Compare Novo Nordisk A/S (NVO) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs D Wave Quantum Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while D Wave Quantum Inc trades at $14.57 (market cap $5.54B). The key difference: Novo Nordisk A/S is far larger — about 29.8× D Wave Quantum Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and D Wave Quantum Inc for 32 Days on average.
| NVO | QBTS | |
|---|---|---|
Market Cap | $165.31B | $5.54B |
Volume | 11,432,838 | 16,671,452 |
Sector | Health | Technology |
52-Week High | $63.98 | $44.78 |
52-Week Low | $35.29 | $12.98 |
Typical Hold Time | 116 Days | 32 Days |
Enterprise Value | $179.56B | $5.04B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
D-Wave Quantum (QBTS) trades at $14.60, down 4.07% with a bearish technical signal despite unanimous analyst buy ratings and a $34.38 consensus target. The quantum computing company shows concerning fundamentals with a P/S ratio of 421.36 and negative profitability metrics, including a -2,001.59% net income margin. Recent quarterly earnings have been mixed, missing expectations in Q4 2025 and Q2 2026 while beating in Q1 2026.
While analyst optimism remains high with 100% buy ratings, significant financial risks persist including ongoing losses, negative cash flow projections for 2026, and multiple fraud investigations. The stock faces substantial execution risk in the competitive quantum computing space, though long-term potential exists if the company can achieve commercial scalability and positive cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
